SAB Biotherapeutics, Inc. is a biotechnology company based in the United States, specializing in the development and production of monoclonal antibodies for the treatment of various diseases. Their platform utilizes transchromosomal production technology to create monoclonal antibodies using genetically modified animal production systems. These antibodies have a wide range of applications in the treatment of oncological, infectious, and autoimmune diseases. SAB Biotherapeutics focuses on innovative solutions in drug development and therapies aimed at improving human health. Shares of SAB Biotherapeutics, Inc. could be an interesting investment opportunity for investors following the biotechnology sector and seeking innovative and promising companies in drug development.